Adrenoleukodystrophy

Adrenoleukodystrophy
Specialty	Endocrinology, genetics

Adrenoleukodystrophy (ALD) (also known as Schilder's Disease and Sudanophilic [Leukodystrophy] is a rare inherited disorder that leads to progressive brain damage, failure of the [adrenal gland] and eventually death. ALD is one disease in a group of inherited disorders called Leukodystrophies. Adrenoleukodystrophy progressively damages the myelin, a complex fatty neural tissue that insulates many nerves of the central and [peripheral nervous system]s. Without myelin, nerves are unable to conduct an [impulse], leading to increasing [disability] as myelin destruction increases and intensifies. An essential protein, called a transporter protein, is missing in sufferers. This protein is needed to carry an enzyme which is used to break down long chain fatty acids found in the normal diet. A build up of these long chain fatty acids (in the body) due to this can cause damage to the brain and the adrenal gland. The victims of ALD are nearly always male, with about one in five women carrying the disease developing a milder form in adult life. There are several different types of the disease which can be inherited in two different ways. It is more commonly inherited as an X-linked condition.

Although this disorder affects the growth and/or development of myelin, Leukodystrophies are different from demyelinating disorders such as multiple sclerosis where myelin is formed normally but is lost by immunologic dysfunction or for other reasons.

Symptoms

The clinical presentation is largely dependent on the age of onset of the disease. The most severe type is the childhood cerebral form for most likely the male, which normally occurs between the ages of 4 and 10 and is characterized by failure to develop, seizures, ataxia, adrenal insufficiency, as well as degeneration of visual and auditory function. This form can also occur in adolescents and very rarely in adults.

In another form of ALD which primarily strikes young men, the spinal cord dysfunction is more prominent and therefore is called adrenomyeloneuropathy, or "AMN." The patients usually present with weakness and numbness of the limbs and urination or defecation problems. Most victims of this form are also males, although some female carriers exhibit symptoms similar to AMN.

Adult and neonatal (which tend to affect both males and females and be inherited in an autosomal recessive manner) forms of the disease also exist but they are extremely rare. Some patients may present with sole findings of adrenal insufficiency (Addison's disease). ALD also causes uncontrollable rage in some cases.

Diagnosis

The diagnosis is established by clinical findings and the detection of serum long chain fatty acid levels. MRI examination reveals white matter abnormalities, and neuroimaging findings of this disease are quite reminiscent of the findings of multiple sclerosis. Genetic testing for the analysis of the defective gene is available in some centers.

Pathophysiology

X-linked

The most common form of ALD is X-linked (the defective gene is on the X chromosome, location Xq28), and is characterized by excessive accumulation of very long chain fatty acids (VLCFA) — fatty acids chains with 24–30 carbon atoms (particularly hexacosanoate, C26) in length. This was originally described by Moser et al in 1981. So, when the ALD gene was discovered in 1993, it was a surprise that the corresponding protein was in fact a member of a family of transporter proteins, not an enzyme. It is still a mystery as to how the transporter affects the function of the fatty acid enzyme and, for that matter, how high levels of very long chain fatty acids cause the loss of myelin on nerve fibers.

The gene (ABCD1 or "ATP-binding cassette, subfamily D, member 1") codes for a protein that transfers fatty acids into peroxisomes, the cellular organelles where the fatty acids undergo β-oxidation. A dysfunctional gene leads to the accumulation of very long chain fatty acids (VLCFA).

The precise mechanisms through which high VLCFA concentrations cause the disease are still unknown as of 2005, but accumulation is severe in the organs affected.

The prevalence of X-linked adrenoleukodystrophy is approximately 1 in 20,000 individuals. This condition occurs with a similar frequency in all populations.

Autosomal

Autosomal adrenoleukodystrophy has been associated with PEX1, PEX5, PEX10, PEX13, and PEX26.

Screening

Neonatal screening is likely to become available which may permit proactive monitoring and treatment.

Treatment

While there is currently no cure for the disease, some dietary treatments, for example, a 4:1 mixture of glyceryl trioleate and glyceryl trierucate (Lorenzo's oil) in combination with a diet low in VLCFA, have been used with limited success, especially before disease symptoms appear. A 2005 study shows positive long-term results with this approach. A 2007 report also appraises "Lorenzo's oil". See also the Myelin Project.

Bone marrow transplantation has been proven to help ALD who are either presymptomatic or exhibiting mild symptoms early in the course of the disease.

Lovastatin is an anticholesterol drug that appears to help, but researchers are unsure as to the mechanism of action.

Prognosis

There is no current cure for ALD and any treatment is purely symptomatic. Progressive neurological degeneration makes the prognosis generally poor. Death occurs within 1-10 years of presentation of symptoms.

Research

Active clinical trials :[1]

• Glyceryl Trioleate (Lorenzo's Oil)
• Beta Interferon and Thalidomide
• Combination of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil)
• Hematopoietic stem cell transplantation

Famous patients

Lorenzo Michael Murphy Odone (born May 29, 1978) is probably the most famous patient with ALD. His parents Augusto and Michaela Odone, frustrated by the limited research available, sparked the invention of "Lorenzo's oil", which is the first agent to have shown therapeutic benefit in halting the destruction of the myelin sheathing of nerves caused by this disease. The quest for a treatment for Lorenzo was depicted in the 1992 film Lorenzo's Oil, and is the subject of the Phil Collins song "Lorenzo" (on his 1996 album Dance Into The Light).

External links

• Template:DMOZ
• adrenoleukodystrophy at NINDS
• Images of ALD at USUHS
• Adrenoleukodystrophy at National Center for Biotechnology Information
• US Patent 5,331,009 — Patent to Croda International Plc on treating ALD with special oil composition inspired by Augusto Odone
• http://www.aldlife.org